JAMA Network Home
Sign In
Research Letter

Trends in Formulary Coverage of Nonprotected Class Drugs Granted FDA Accelerated Approval

JAMA Network Open 10.1001/jamanetworkopen.2025.36089

October 07, 2025 at 11:00 AM EDT

Read the full article

This cross-sectional study examines the trends in Medicare Part D formulary coverage of nonprotected class drugs granted accelerated approval by the US Food and Drug Administration.

Corresponding Author: Shelley A. Jazowski, PhD, MPH, Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, 525 Vine St, Ste 310, Winston-Salem, NC 27101 (shelley.jazowski@advocatehealth.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.36089?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=100725

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks